Home › Trials › NCT05667064

Post-marketing surveillance of IMJUDO and IMFINZI for liver cancer treatment in Japan

Specific Use-results Study of IMJUDO Intravenous Infusion 25 mg, 300 mg / IMFINZI Intravenous Infusion 120 mg, 500 mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma

Observational AstraZeneca · NCT05667064

This study is testing the safety of the treatments IMJUDO and IMFINZI for people in Japan with liver cancer who can't have surgery, to see how they work in real life.

Quick facts

Study typeObservational
Enrollment300 (estimated)
SexAll
SponsorAstraZeneca Industry-sponsored
Locations91 sites (Aichi and 90 other locations)
Trial IDNCT05667064 on ClinicalTrials.gov

What this trial studies

This investigation aims to collect safety data on patients with unresectable hepatocellular carcinoma (HCC) who are treated with either the combination therapy of IMJUDO and IMFINZI or IMFINZI monotherapy in a real-world setting. The study will follow patients receiving these treatments under actual use conditions as part of post-marketing surveillance. It is designed to comply with Japan's regulations on good post-marketing study practices and will contribute to the ongoing assessment of the safety profile of these therapies.

Who should consider this trial

Good fit: Ideal candidates for this study are patients diagnosed with unresectable hepatocellular carcinoma who are receiving IMJUDO and IMFINZI combination therapy or IMFINZI monotherapy.

Not a fit: Patients who are not receiving IMJUDO or IMFINZI for their liver cancer will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable safety information that enhances treatment options for patients with unresectable HCC.

How similar studies have performed: Other studies have shown success with similar post-marketing surveillance approaches, indicating the potential for valuable insights into treatment safety.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

All patients who receive IMJUDO and IMFINZI combination therapy or IMFINZI monotherapy for their unresectable HCC.

-

Exclusion Criteria:

-

Where this trial is running

Aichi and 90 other locations

+41 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Unresectable Hepatocellular Carcinoma
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.